Из последнего
NEJM, 2011; 365:1284-1292:
[
Ссылки доступны только зарегистрированным пользователям ]
Цитата:
|
...the use of suppressive therapy with 300 mg of oral acyclovir per square meter per dose administered three times daily for 6 months after initial treatment of neonatal HSV disease. Babies with skin, eye, and mouth disease can benefit because this therapy helps to prevent skin recurrences, whereas babies with CNS disease may have additional benefit with respect to neurodevelopmental outcomes. There are no controlled data that s uggest that suppressive therapy administered longer than 6 months or with the use of higher doses of oral acyclovir is beneficial...
|
Редакционный комментарий [
Ссылки доступны только зарегистрированным пользователям ]